



CRT Workshop
“Translation of genomics into routine cardiological
practice”

23-34 March 2023 – Marriott Munich Airport Hotel

Faculty Biographies

- [Prof. Stefanie DIMMELER, Germany](#)
- [Prof. Perry ELLIOTT, UK](#)
- [Dr. Leticia FERRI, USA](#)
- [Dr. Paul NIOI, UK](#)
- [Dr. Chris O'DONNELL,](#)
- [Prof. Ulf LANDMESSER, Germany](#)
- [Prof. Thibaud DAMY, France](#)
- [Prof. Mauro GIACCA, UK](#)
- [Prof. Christian KUPATT, Germany](#)
- [Dr. Weinong GUO, United States](#)
- [Dr. Maryam KAVOUSI, Netherlands](#)
- [Dr. Heribert SCHUNKERT, Germany](#)
- [Dr. Antonio GOMEZ-OUTES, Spain](#)
- [Dr. Emmanouil ZOURIDAKIS, UK](#)



Prof. Stefanie Dimmeler, Germany

Stefanie Dimmeler is born on 18.07.1967 in Ravensburg, Germany.

Dr. Dimmeler received her under-graduate, graduate, and Ph.D. degree from the University of Konstanz in Konstanz (Germany) and then completed a fellowship in Experimental Surgery at the University of Cologne and in Molecular Cardiology at the University of Frankfurt (Germany). She is Professor of Experimental Medicine (since 2001) and Director of the Institute of Cardiovascular Regeneration, Center for Molecular Medicine at the University of Frankfurt since 2008.

In the last years, she has been invited as a speaker in more than 300 national and international meetings and seminars and has presented various keynote lectures. She also received several awards.

She is also spokesperson of the “Cardiopulmonary Institute” (CPI) which is funded by the Excellence Strategy Program of the German Research Foundation and spokesperson of the German Center for Cardiovascular Research (DZHK).

She also received three Advanced Investigator Grants by the European Research Community (ERC).

Her group elucidates the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new cellular and pharmacological therapies for improving the treatment of cardiovascular disease. Ongoing research focuses on epigenetic mechanisms that control cardiovascular repair, specifically non-coding RNAs.



Prof. Perry Elliott, UK

Perry Elliott is Professor of Cardiovascular Medicine at University College London and a Senior Investigator of the UK National Institute for Health Research.

He is director of the UCL Institute of Cardiovascular Science UCL and a consultant cardiologist at St. Bartholomew's Hospital London, UK.

He is Chairman of the ESC Heart Academy and past chair of the ESC Council on Cardiovascular Genomics, the ESC Working Group on Myocardial and Pericardial Diseases (2010–2012) and the Executive Committee for the European Outcomes Research Programme registry on cardiomyopathies.

He is President of Cardiomyopathy UK and an executive Editor for the European Heart Journal.



Dr. Leticia Ferri, BMS

Leticia Ferri, MD MSc MBA PhD

Executive Director, Mavacamten Lead US Medical, Cardiovascular & Established Brands

Dr. Leticia Ferri serves as Executive Director for US Medical, Cardiovascular & Established Brands as Mavacamten Lead.

Leticia has been the Mavacamten US Medical Lead since 2022. Her career at Bristol Myers Squibb started in 2010 in Brazil as Scientific Advisor. Later, she worked at BMS Canada and since 2013 has been based at BMS offices in New Jersey working at different functions at medical affairs teams across different therapeutic areas, and for 2 years, Leticia was the BMS Global lead for OLA (Organization for Latino Advancement).

Leticia's clinical and research training includes MD, Internal Medicine and Endocrinology residency & Board Certification in Brazil, Master of Science from Maringá State University in Brazil, Master of Clinical Epidemiology from the University of Toronto in Canada, a PhD from the University of São Paulo in Brazil, and MBA from Cornell University.

Leticia serves on the Board of Directors for Greater Trenton, Cornell Johnson Recent Alumni Council and Advisor for Rutgers School of Arts and Sciences.



Dr. Paul NIOI, Alnylam

Paul Nioi, PhD

Vice President, Discovery and Translational Research

Paul joined Alnylam in March 2018 and is responsible for leading the Discovery and Translational Research function. He has overall responsibility for new target identification/validation, biomarkers and all preclinical drug discovery programs. Building on his depth of prior experience, he also leads the Alnylam Human Genetics center which focuses on identification of new drug targets from large genotype-phenotype datasets.

Paul has over 18 years of biotech and pharma experience. He joined Alnylam following a tenure at Amgen and deCODE genetics where he held roles of increasing responsibility. Most recently he was Director of the Translational Systems Biology group and led a large team that was focused on making discoveries from human genetics to influence target selection.

Paul obtained his academic training at the University of Edinburgh (BSc, Pharmacology) and the University of Dundee (PhD, Molecular Biology).



Dr. Chris O'DONNELL, Novartis

CHRISTOPHER J. O'DONNELL, MD, MPH, FAHA, FACC

**Vice-President, Global Head, Cardiovascular and Metabolism Translational Medicine,
Novartis Institutes for Biomedical Research, Cambridge MA**

Dr. O'Donnell is an internationally recognized cardiologist-investigator and leader of population science research to advance prevention and treatment of cardiovascular and metabolic diseases. He received his Doctor of Medicine and Public Health degree from Harvard University and completed residency (Internal Medicine) and fellowship (Cardiology) at the Massachusetts General Hospital, where he served on faculty for two decades. From 1996-2015, he was employed in the National Heart, Lung and Blood Institute (NHLBI) and its landmark Framingham Heart Study (FHS). He served as Associate Director and Scientific Director of Genomics at FHS, and became a Tenured Senior Investigator and Chief, Cardiovascular Epidemiology and Human Genomics Branch, NHLBI Intramural Research. From 2015-2021, he was Chief of Cardiology and Director, Center for Population Genomics, VA Boston Healthcare System. As Co-PI and Chief Scientist of the US VA Million Veteran Program, he directed the science program of the largest US biobank. Dr. O'Donnell is a highly regarded leader of international genomics consortia and research networks, including the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. His research team has discovered multiple novel gene variants for atherosclerosis, coronary artery disease, obesity and other cardiometabolic diseases and risk factors. In 2020, he became Professor of Medicine, Harvard Medical School. In March 2021, he joined Novartis Institutes for Biomedical Research as Global Head, Cardiovascular and Metabolism Translational Medicine. In Novartis, he oversees a translational medicine drug discovery program addressing large unmet needs in treatment and prevention of cardiometabolic diseases, and he provides leadership in the application of genomics to drug discovery and translation. He has authored >700 peer-reviewed articles and other publications, including reports in high impact journals such as NEJM, JAMA, and Nature. He is listed multiple times since 2017 in the top 1% on the Clarivate Analytics Most Highly Cited Researchers lists.



Prof. Ulf LANDMESSER, Germany

Professor Ulf Landmesser acts since January 2023 as Director of the Department of Cardiology, Angiology and Intensive Care Medicine, Campus Benjamin Franklin at the Deutsche Herzzentrum der Charité (DHZC) and since June 2022 also as the Director of the newly established Friede Springer – Cardiovascular Prevention Center@Char-ité.

After his medical studies at the Medical School of Hannover (Germany), the University of Connecticut in Farmington (USA) and the National Heart&Lung Institute in London (UK), he specialized in Internal Medicine and Cardiology at the Medical School of Hannover. In 2000/2001 he performed a post-doctoral fellowship focusing on vascular biology at the Department of Cardiology at the Emory University School of Medicine, Atlanta (USA) as a scholar of the Alexander von Humboldt Foundation and received the Outstanding Fellows in Cardiology Special Recognition Award.

In 2007, he was called as Senior Consultant Cardiologist with a focus on acute and interventional cardiology and as director of translational cardiovascular research to the Department of Cardiology at the University Hospital of Zurich (Switzerland), where he later acted as Vice-Chairman of the Department of Cardiology. From 2014 until the merger with Deutsches Herzzentrum Berlin on 01.01.2023 he acted as Chairman of the Department of Cardiology at the Charité – Universitätsmedizin Berlin as well as from 2016 on as Medical Director of the Charité Center for Cardiovascular Medicine.

He serves as a Member of the Editorial Board of the International Journal of Cardiology and since 2008 Professor Landmesser serves as Deputy Editor of the European Heart Journal, the leading cardiovascular journal in Europe.

He has a particular research interest in translational and clinical development of novel therapeutic and management strategies for prevention and treatment of atherosclerotic cardiovascular disease.

He has more than 500 publications and an h-index of 99. He has contributed to several ESC/EAS guidelines and EAS consensus papers. Since 2019 is under the 1%-Highly Cited Researchers.



Prof. Thibaud DAMY, France

Thibaud Damy, MD PhD

Head of the French Referral Center for Cardiac Amyloidosis

Past president of French Heart Failure and Cardiomyopathy Group of the French Society of Cardiology and European Heart Failure Association. Department of Cardiology, Assistance Publique – Hôpitaux de Paris, Paris, France

Professor Damy's main field of interests are heart failure and amyloidosis, extending from its epidemiology and pathophysiology through to its diagnosis and treatment. His particular current interests include early cardiac diagnostic markers, from biology to imaging. He is a co-author of more than 2000 articles (half of them focusing on amyloidosis).

Thibaud Damy qualified in medicine at the University of Paris XI, Paris, France, in 1996. After a period of postgraduate cardiology training in several Parisian hospitals, he specialised in heart failure and cardiomyopathy and obtained his PhD on the effect of nitric oxide on heart failure at the University of Paris VII. Professor Damy subsequently took up a position as Senior Lecturer in Cardiology and Honorary Consultant Cardiologist at Henri Mondor Hospital, Créteil, France, and later as Senior Research Fellow at the Academic Cardiology Department of Professor John G Cleland at the University of Hull, Hull, UK. In 2011, he was appointed Professor in Cardiology and became the Head of the Heart Failure and Cardiomyopathy unit at Assistance Publique – Hôpitaux de Paris, Paris, France.

In 2009, Professor Damy created the "Mondor Amyloidosis Network", which involves all the clinical facilities for the diagnosis and treatment of amyloidosis, in addition to a clinical research team. It rapidly became an important multidisciplinary network involving more than 40 healthcare professionals in the hospital. In 2014, they created the GRC Amyloid Research Institute. Since 2010, more than 5.900 patients have been referred to the centre for suspicion of cardiac amyloidosis and more than 2100 had a diagnosis confirmed. Professor Damy and his team created a wide educational programme to improve the knowledge and quality of life of the patients: Amylo Patient Education Program (Amylo-PEP). In 2017, the Mondor Amyloidosis Network was appointed as referral centre for cardiac amyloidosis by the French Health Ministry. Since 2017, 25 centres gather the French Amyloidosis Network leading the path to the creation of the French National Amyloidosis Registry (HEAR).



Prof. Mauro GIACCA, UK

Mauro Giacca is Head of the School of Cardiovascular Medicine & Sciences at King's College London. Until 2019, he has served as the Director-General of ICGEB, a United Nations organization in Trieste, Italy.

He has obtained his Degree in Medicine from the University of Trieste, Italy and his PhD in Virology from the University of Genoa, Italy.

He is considered an expert in the generation of viral vectors for cardiovascular applications and the development of novel biologics for cardiac repair and regeneration.

Prof Giacca is a Fellow of the Academy of Medical Sciences of the United Kingdom and serves as the President of the International Society for Heart Research - European Section.

He is the founder of two startups that develop advanced therapies for cardiac protection and regeneration.



Prof. Christian KUPATT, Germany

Prof. Dr. med. Christian Kupatt - Executive Senior Physician at the department of Cardiology of the Klinikum rechts der Isar, Technical University of Munich, Germany

Work specifics: Physician Scientist

Interventional Cardiologist (PCI, Structural Heart disease) and principal investigator (preclinical studies for gene & cell therapy, gene editing After completing Med School (Ludwig-Maximilians-University of Munich), I joined clinical cardiology in 1991. From 1993 to 1997, I was working as scientific fellow to the Department of Physiology in Munich and the Cardiovascular Research at Brigham (Boston, USA), focusing on vascular and inflammatory components of cardiac reperfusion injury. Returning to the

Cardiology Department of the LMU University Clinic, I pursued my clinical career as an interventional cardiologist, treating coronary artery disease as well as structural heart disease. Simultaneously, I established and continuously expanded a lab for large animal research of ischemic heart disease and gene/cell therapy. Instructed by treating patients presenting with acute myocardial infarction and chronic ischemic heart disease, I put emphasis on treatment of reperfusion injury via anti-microRNA agents and AAV-based gene therapy¹.

The AAV vector platform fitted well to gene editing studies like correcting Duchenne's muscular dystrophy² and other forms of inherited cardiomyopathy. Additional pre-clinical animal models such as hypertrophic heart disease and ischemic heart failure are used to test molecular interventions modulating non-coding RNAs. In addition to an ERC Advanced Grant (2021), my lab is funded by the German Research Foundation (DFG) as well as by the German Centre for cardiovascular Research (DZHK) and the Federal Ministry of Education and Research

To get into contact with me: +49 (0) 89 4140 9086 - e-mail: christian.kupatt@tum.de



Dr. Weinong GUO, Alnylam

Dr. Weinong Guo, MD PhD, joined Alnylam in May 2021 and is currently Senior Vice President of Clinical Research. In this role, he leads the Clinical Research team and oversees the clinical development programs in CardioMetabolic & CNS disease areas.

Before joining Alnylam, he worked in CardioRenalMetabolic Development Unit in Novartis for about 14 years where he played a key role in a number of high-priority clinical development programs including successful registration and life cycle management of Entresto® (sacubitril/valsartan) for chronic heart failure, hypertension and myocardial infarction. Dr. Guo spent 20 years in the industry including Solvay and Schering-Plough during his early career.

Dr. Guo received his MD degree from Soochow University in China and his PhD from Nagoya University in Japan. He completed his cardiology training at 2nd Affiliated Hospital at Soochow University, and an AHA postdoctoral fellowship in cardiac electrophysiology and pharmacology at Washington University in St. Louis before joining the industry. He has been a Fellow of American College of Cardiology since 2005.



**Dr. Maryam KAVOUSHI,
Netherlands**

Maryam Kavousi MD PhD is Associate Professor of Epidemiology at Erasmus University Medical Center in Rotterdam, the Netherlands.

Her research is focused on epidemiology of cardio-metabolic disorders with an emphasis on sex and gender differences.

Her studies mainly involve primary prevention of cardio-metabolic disorders; covering the course from an asymptomatic phase, to advent of sub-clinical disease, to overt disease.

Her research comprises both traditional and novel cardio-metabolic risk factors; including omics and markers representative of different pathophysiological pathways.

Maryam Kavousi has been recognized by receiving multiple awards and research grants from national and international organizations and programs.

Dr. Kavousi is currently chair of the Population Science and Public Health Section of the European Association of Preventive Cardiology (EAPC).



**Prof. Heribert SCHUNKERT,
Germany**

Heribert Schunkert, MD is Professor of Cardiology of the Technische Universität München and Director of the Cardiology Department, German Heart Centre Munich since 2012. He completed a research fellowship at Brigham and Women's Hospital, Boston, USA and clinical fellowships at Beth Israel Hospital, Universitätsklinikum Regensburg, and the Massachusetts General Hospital, Boston, USA, before he became assistant and associate professor in Regensburg. From 2002-2012 Prof. Schunkert was Director of Internal Medicine and Cardiology at the University of Luebeck. He conducts research in the molecular genetics of multifactorial cardiovascular disease, coordinates several EU- and BMBF-sponsored projects as well as the European-American Leducq network CAD genomics to identify the genetic roots of myocardial infarction. He is the author of more than 700 publications in international journals.



Dr. Antonio GOMEZ-OUTES, Spain

Antonio Gómez-Outes, MD, PhD, MSc, specialist in Clinical Pharmacology, is currently a consulting physician and Head of Cardiovascular and Respiratory Medicines in the Clinical Division of the Spanish Medicines Agency (AEMPS). He is also one of the members of the Cardiovascular Working Party of the European Medicines Agency (EMA-CVSWP). As AEMPS clinical assessor, he has been involved in numerous European scientific advice and registration procedures for cardiovascular medicines since 2008, and also in regulatory procedures and activities related to hemophilia gene therapy. As a member of the EMA-CVSWP, he has contributed to a series of EMA guidelines on clinical investigation in the cardiovascular field since 2010. He has also participated as an EMA expert in many international meetings, including some of the previous Cardiovascular Round Table meetings organized by the European Society of Cardiology (ESC-CRT).



Dr. Emmanouil ZOURIDAKIS, UK

Dr Emmanouil Zouridakis is Leading Senior Medical Assessor at the UK Medicines & Healthcare Products Regulatory Agency (MHRA), working in the Assessment Unit of the Licensing Division that is responsible for cardiovascular, diabetes and renal products.

Dr Zouridakis is a cardiologist and worked at different teaching hospitals before joining the MHRA in 2004. During his time at MHRA he has been the lead clinical assessor in a wide range of European and National regulatory procedures involving cardiovascular and diabetes medicines, drug/device combinations, class-wide benefit-risk reviews and scientific advices to companies. He is a principal assessor at the Cardiovascular Expert Advisory Group of the UK Commission on Human Medicines.